Tonix Pharmaceuticals (TNXP) Investor presentation summary

Clinical pipeline and regulatory milestones

• TNX-102 SL for fibromyalgia has completed two pivotal Phase 3 trials with statistical significance and an NDA submitted; FDA decision expected by August 15, 2025.

• TNX-102 SL is a proprietary sublingual cyclobenzaprine formulation designed for improved absorption and reduced metabolite accumulation, showing durable pain reduction and good tolerability.

• TNX-1300, a biologic cocaine antidote, is in Phase 2 with FDA Breakthrough Therapy Designation; Phase 2 study ongoing.

• TNX-1500, an anti-CD40L monoclonal antibody, completed Phase 1 with positive topline results and is advancing to Phase 2 for organ transplant rejection.

• Additional pipeline assets target acute stress disorder, autoimmune conditions, and broad-spectrum antivirals, with government and academic partnerships supporting development.

Marketed products and commercial strategy

• Two proprietary migraine drugs, Zembrace and Tosymra, are marketed for acute migraine, with rapid onset and patents extending to 2036 and 2031, respectively.

• Commercial infrastructure includes supply chain, managed care, and specialty sales force, with plans to launch TNX-102 SL for fibromyalgia.

• Fibromyalgia care is concentrated among specialized providers, enabling targeted marketing.

Intellectual property and partnerships

• TNX-102 SL is protected by multiple US and international patents, with composition and method-of-use claims extending market exclusivity into the 2030s and 2040s.

• Strategic collaborations with leading institutions support clinical development in organ transplantation, acute stress disorder, cocaine intoxication, and antiviral research.